Based on the PP of $87 million less the loan retirement and other expenses, and including the ROFR agreement I would guessitmate that the company has somewhere around $10 million left heading into 2018....enough to last 2 to 3 months.  

Where will they get the money needed to complete BETonMACE, other trials and to fund operations going forward into 2018?  I think the most logical source of funding, (the lion's share of it in any event) is Shenzhen Hepalink, either in the form of licensing deal(s) and/or more placements.  

I just hope they start engaging in some activity to promote Apabetalone.....otherwise HL might be getting another massive bargain like they did with the $87 million placement.  At the very least I expect them to be professional in their corporate communication so as to present a postive image to the market place.